All In Biotech

Investigational drug · Phase 3

Larazotide Acetate

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease, Celiac Disease in Adolescents.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

30

Any phase or sponsor naming "Larazotide Acetate"

First trial start

2027

Feb 2027

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Larazotide Acetate", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Celiac Disease
  • Celiac Disease in Adolescents

Approved drugs for the same conditions: Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Larazotide Acetate" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 44 on PubMed

Also in development for Celiac Disease

  • AmlitelimabSAR445229Phase 39 trials

    Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease

  • TEV-53408Phase 32 trials

    Teva · Vitiligo, Celiac Disease

  • DONQ52Phase 21 trial

    Chugai Pharmaceutical · Celiac Disease

  • FB102Phase 21 trial

    Forte Biosciences, Inc. · Celiac Disease

  • KAN-101Phase 21 trial

    Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease

  • TAK-101Phase 21 trial

    Takeda · Celiac Disease

  • ZED1227Phase 21 trial

    Dr. Falk Pharma GmbH · Celiac Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.